AntiArrhythmic Drugs Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Antiarrhythmic Drug Characteristics

A
  • ALL target ion channels in the heart either directly or indirectly
  • many are both anti-and pro-arrhythmic. Some are associated with severe or even life threatening adverse effects
  • blockade for cardiac ion channels also contributes to the proarrhythmic adverse effects of a large number of non-cardiac drugs
  • ONLY beta-blockers (class II) have been shown to be associated with a significant reduction of mortality
  • radiofrequency catheter ablation may produce permanent cures in many forms of Arrhythmias, implantable cardioverterdefibrillator (ICD) has the potential for prolonging survival by terminating VT/VF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

2 major differences in AP (pacemakers vs. working myocytes)

A
  • resting potential (diastolic potential is more depolarized in nodal cells)
  • conduction velocity is almost 100x’s faster than pacemaker cells

allows for selectivity for anti-arrhythmic drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Major classes of ion channels in the heart

A
Na Channel
Transient Outward K channel (Ito)
Sustained K channels (Ik [split into IKr and IKs])
IK1 channels (or inward rectifier IK1)
L-type Ca channels
Pacemaking channel (If)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

5 Phases of AP

A

0: upstroke (rapid opening and inactivation of Na channels. Very large but brief inward Na current)
1: initial repolarization (activation and inactivation of transient outward K current)
2: plateau phase (opposing Ca and K current): they balance each other and relatively small net current going on, which is hwy you have a prolonged plateau phase
3: final repolarization (inward rectifier K current, brings the voltage back to the resting phase. Sustained outward current that holds the voltage at a hyperpolarized level)
4: diastolic phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Propagation of Action Potential (factors)

A

Speed

Magnitude

***larger inward current—

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Na channel Blockers (e.g. Quinidine) (class I antiarrhythmics)

A

AP conduction is determined by the size of inward current, blockade of Na current reduces conduction

  • the membrane potential of DISEASED CELLS is less negative, as a result, more Na channels are inactivated, generating a slow-conducting abnormal AP
  • Na channel blockers target open or inactivated Na channel, suppressing abnormal AP but leaving normal AP alone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

K channel Blockers (class III antiarrhythmics) (e.g. ibutilide)

A
  • if you apply these, tilts the balance of K and Ca currents in the plateau phase (2) toward Ca influx. Prolongs the entire AP duration and refractory period
  • prevents tachycardia and normal myocardium being triggered by diseased areas
  • excessive prolongation of APD is pro-arrhythmic and can lead to arrhythmogenic triggered activities and polymorphic VT, torsade de points
  • genetic mutations of cardiac K channels prolongs APD and QT interval, resulting in idiopathic Long QT Syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Ca channel blockers (Class IV arrhythmics) (e.g diltiazem)

A
  • SA and AV node cell AP upstroke mediated entirely by L-type Ca current
  • Ca Blockers decrease conduction velocity, mainly in the AV node. This controls the transmission of high atrial rate to ventricles in Afib (rate control)
  • iCaL blockade reduces AP duration and contractility in working myocytes. Negative inotropic effects will WORSEN HF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Beta-Blockers (class II arrhythmics) (e.g. metoprolol)

A
  • decrease pacemaker activity, and is effective in treating sinus tachycardia
  • modulates If current that is activated or inhibited by sympathetic/parasympathetics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cholinergic Blocker (e.g. atropine)

A

-increases If, and is effective in treating sinus bradycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Abnormal Automaticity

A

Simple: either too fast or too slow
-increased vagaries tone inhibits If, leads to Sinus bradycardia
Tx: either atropine (muscarinic receptor blocker) or B agonist (isoproterenol)
-increased sympathetic tone stimulates If, leads to Sinus Tachycardia
Tx: B-blocker (metoprolol), Ca Channel Blocker (Diltiazem):reduces conduction veloicty, increases AP threshold and time to threshold (greater effect on AVN), K channel blocker (amiodarone): prolong APD thus decreases AP rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Triggered Activity

A

-NOT a self-generating rhythm (unlike automaticity)
-spontaneous excitation of myocyte “triggered” by preceding impulse
-theses are single cell phenomena that can propagate and lead to cardiac arrhythmias
Requires 2 things
-voltage has to be above threshold or the channels will never open
-AND you need enough Na channels in the closed state to be re-opened

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Early Afterdepolarization (EAD)

A
  • occurs during excessive prolongation of AP
  • due to very long AP, the Na and even Ca channels have enough time to recover back into closed state. The voltage spends quite a long time above threshold. Not a full recovery of Na channels but enough to fire an AP. We have the 2 conditions necessary to fire spontaneously
  • the cell will fire a second AP on rope of the first AP
  • associated with slow HR and AP prolongation
  • happens DURING an AP
  • might be underlying mechanisms of arrhythmogenesis in Long QT syndrome

Tx:

  • treat offending condition (ischemia, K channel blockade)
  • Na channel blockers (e.g. Lidocaine)
  • B-blockers: in long QT syndrome (suppress L-type Ca channel, stimulate K channels: net increase in outward current)
  • ***K channel blockers are contraindicated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Delayed Afterdepolarization (DAD)

A
  • associated with fast rate and is the result of CA overload of cell
  • happens AFTER the complete repolarization of an AP and can trigger a second or a series of additional APs
  • more likely in the presence of catecholamines

Tx:

  • B-Blockers: lower HR and reduce Ca influx and uptake
  • Na Channel Blockers: to block the generation of spontaneous AP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Long QT Syndrome

A
  • caused by mutations of cardiac channel genes (IKs, IKr, Na, L-type or Ik1), which result in decreased in outward K current or increase in inward Na/Ca current. Leads to longer cardiac APD and development of EADs
  • syncope attacks, SCD due to TdP, a polymorphic VT

Tx:

  • B-blockers: suppress Ca current and stimulates IKr)
  • ICD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Reentry

A

-responsible for majority of clinically significant tachycardia
occurs when there is:
1. Unidirectional blockade of conduction in diseased region
2. Slow Conduction zone in the reentrant circuit: allows recovery from ARP

Tx:

  • K channel blockers (and certain Na channel blockers) to prolong APD and ARP
  • Na channel blockers (target open or inactivated Na channels in diseased region) to block conduction in diseased region
17
Q

AVNRT

A

Tx:
adenosine: drug of choice for rapid termination of AVNRT
-activates A1 receptor, suppresses adenylate cyclase and eventually blocks
Digoxin: increases ACh release
Beta blockers
Ca Channel Blockers

Long term: ablation of the slow pathway

18
Q

Wolff-Parkinson-White Syndrome

A

Tx:
Adenosine, B-Blockers, Ca channel blockers to slow conduction at AVN
Digoxin is contraindicated in adult WPWs, accelerates conduction in the accessory pathway, increases risk of VFib
Certain Na channel blockers (IV Procainamide) to block conduction Of accessory pathway
Ablation of accessory pathway

19
Q

Vaughn Williams Classification

A
I: Na channel blockers
-inhibit depolarization, slows conduction velocity
     Ia: prolong APD
     Ib: shorten APD
     Ic: no effect on APD

II: B-blockers

  • inhibit phase 4 and 0 in the SAN and AVN
  • shorten APD in working myocytes

III: K channel blockers
-prolong APD and ARP

IV: Ca channel blockers

  • major effects on AVN>SA node
  • inhibit phase 0 and prolongs phase 4

Misc: adenosine, digoxin, atropine

20
Q

Class I: Na channel Blockers MOA

A

Na channel blockers (quinidine) have higher affinity for open or inactivated Na channels: use dependent block

  • the longer you use it, the more blockade you get
  • has increased efficacy in slowing and converting tachycardia with minor effects on tissues depolarizing at normal (sinus) rhythm
  • also allows targeting of diseased tissue, where membrane potential is less negative, and more Na channels are in the inactivated state
21
Q

Quinidine

A

First gen Class I drug
-indication: restore or maintain sinus rhythm in Atrial flutter or Fib (rhythm control)
-historically was used to prevent recurrent V Tach or VFib
-class IA: also has class III actions, blocks multiple K channels
Prolongs APD and QT (by up to 25%) significant risk for TdP even at therapeutic or sub-therapeutic concentrations
-intermediate kinetics, t1/2 is about 6 hours
ADE:
-cardiac: QT prolongation, TdP (up to 8% of patients)
-noncardiac: diarrhea, cinchonism, thrombocytopenia

increases mortality post-MI

22
Q

Class II: Beta-blockers

A
  • Most effective drugs in treating arrhythmias and preventing SCD in patients with Ischemic Heart Disease, HF, and congential LQTS
  • Have anti-ischemic Effects due to reduction of HR. Reduce mortality and are the drugs of choice in post-MI patients. Are the most effective drugs for preventing SCD in patients with active CAD
  • Prevent arrhythmic death in HF patients by preventing or reversing electrical remodeling due to sustained B-adrenergic stimulus
  • have less pro-arrhythmic drug effects and are much safer in clinical usage compared with other anti-arrhythmics drugs
23
Q

MOA of Beta-Blockers

A

ICaL Suppression: shortens APD, reduce Ca overload

  • suppresses EAD, DAD, congenital LQTs
  • slows down Conduction in AVN: rate control in AFib

IKr: stimulation
-shortens APD: prevents EAD, congenital LQTs

HCN (If): suppression
-reduced pacemaking rate: prevents sinus tachycardia

NCX: suppresses
-reduces DAD

24
Q

Metoprolol

A

Indication: Tachycardia, CAD

  • post-MI, CHF: mortality benefits and antiarrhythmics effects
  • rate control in Afib
  • congenital LQTs (BUT NOT DRUG-INDUCED LQTs: that’s MgCl)

B1 selective: modest selectivity: safer in patients who experienced bronchospasm in response to non-selective B-blockers (e.g. propranolol)

Short half life: 3-4 hours, extended release for PO

ADE:

  • cardiodepressant: contraindicated in severe HF, severe bradycardia, AV blocker > 1st degree; use with caution with Ca channe lblockers
  • Bronchospasms: contraindicated in asthma
  • other: insomnia, depression, dizziness
25
Q

Class III: K channel Blockers

Amiodarone

A

-considered one of the most effective antiarrhythmic drugs
-one of the most prescribed antiarrhythmic drugs in the US
-has all 4 Vaughan Williams Class Effects (MOA unclear)
-unique PK properties: PO or IV, half-life 10-100 days (2 phases)
Indication:
-effective in acute management of sustained VT
-most effective drug for maintaining sinus rhythm in Afib
-used with ICD in VT/VF to reduce number of shocks

Prophylactic in the peri-op period of cardiac surgery
Decrease Arrhythmias but has no overall mortality benefit post-MI
Role in cardioversion of AFib is limited
Flecainide, ibutilide, and dofetilide are the most effacious agents for Medical conversion of AF
-in the presence of WPW syndrome, procainamide is the drug of choice for converting Afib
Alternative: electrical cardioversion

ADE:
-low cardiac toxicity, low incidence of pro-arrhythmic effects, TdP in <1% of patients 
significant non-cardiac ADE and drug interactions:
-pulmonary fibrosis (1-7%)
-hypotension
-photosensitivity
-hypo or hyper thyroidism
-blue-gray skin
-corneal deposits (>90%) 
-optic neuropathy 
-neuromuscular symptoms (low)

Drug interactions: warfarin, digoxin, statins

Dronedarone: a derivative to overcome amiodarone’s serious systemic side effects was approved for Afib in 2009

26
Q

K Channel Blockers or drugs with Class III Action (exception Amiodarone) ADE

A

Promotes the development of EAD or can convert borderline DAD into EAD, lead to TdP and SCD

27
Q

Class IV: Ca Channel Blockers

Diltiazem

A
  • reduces inward Ca current in nodal cells. Decrease conduction velocity. Effect on AVN»>Sinus Node
  • Indication: rate control in Afib. Termination and suppression of SVT
  • PO or half life 3-4 hours

ADE:

  • cardiac: sinus bradycardia, AV block, negative inotropic effects will worsen HF
  • hypotension due to Vasodilation
28
Q

MOA: Indirect Channel Modulators

A

B-Blockers: usually indirectly thru signaling pathways

Adenosine: can treat SVT and WPW. Acts on ATP to cAMP pathway, activates PKA

Digoxin: blocks Na/K pump. Increases Intracellular Na concentration which reverses the Na/Ca exchanger, increasing intracellular Ca
-also does the same thing in the vagal nerve, raising Ca in vagal nerve, releases ACh, lowering HR and suppression ion channels